Xiao Dong

Mrs. Xiao Dong


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2024 in Advanced Composites and Hybrid Materials
Verified
Journal Article
Closed access
PDF file
HZHanyu Zhang
Hanyu Zhang
MZMingdi Zheng
Mingdi Zheng
MHMeng Hao
Meng Hao
XDXiao Dong
Xiao Dong
GLGemeng Liang
Gemeng Liang
PXPeitao Xie
Peitao Xie

6 April 2026 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
JHJunjie Hang
Junjie Hang
LWLixia Wu
Lixia Wu
LXLi Xiao
Li Xiao
QDQiuhua Duan
Qiuhua Duan
HZHan Zhao
Han Zhao
JCJianhua Chang
Jianhua Chang
Background: The optimal sequence of administering immune checkpoint inhibitors (ICIs) and chemotherapy in advanced esophageal cancer (EC) and gastric cancer (GC) remains to be established. Understanding how this sequencing affects overall survival (OS) is crucial for optimizing treatment strategies. Methods: This multicenter study enrolled 334 patients diagnosed with advanced EC or GC between January 2018 and October 2024. To reduce confounding biases, propensity score matching (PSM) was applied, resulting in 292 matched patients categorized into two groups, including those receiving ICIs first (IF) and those receiving chemotherapy first (CF). Results: Following PSM, Kaplan–Meier analysis showed that the CF group had a significantly prolonged median OS compared to the IF group (16.80 vs. 14.60 months; p = 0.014). These findings were further corroborated in the unmatched cohort (16.60 vs. 14.60 months; p = 0.012). Multivariable analysis identified ECOG performance status, PD-L1 expression, antibiotic use, and line of ICI treatment as independent prognostic factors, whereas the i mmunochemotherapy administration sequence did not retain independent prognostic significance. Subgroup analysis revealed that among patients receiving first-line immunochemotherapy, those in the CF group had significantly longer OS (16.50 vs. 12.30 months; p = 0.004), with no significant difference observed for those beyond first-line treatment ( p = 0.862). The objective response rate and disease control rate were comparable between the two groups. Conclusions: This study suggests that administering chemotherapy prior to immunotherapy appears to improve OS in patients with advanced EC and GC, particularly when initiated as first-line treatment. These findings highlight the need for further research into biomarkers and personalized treatment strategies to enhance patient outcomes.